Table of Content

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Market Definition
Key Takeaways
Key Recommendations
Chapter 4 Market Breakdown by End User
Hospitals
Research Institutes
Chapter 5 Market Breakdown by Application
Cancer
Neurological Diseases
Cardiovascular Diseases
Diabetes
Other Diseases
Chapter 6 Market Breakdown by Region
North America
United States
Canada
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Rest of World
Chapter 7 Patent Review and New Developments
Recent Developments
Chapter 8 Competitive Landscape
BioMerieux Inc.
Recent Developments
F. Hoffmann-La Roche Ltd.
Recent Developments
Merck KGaA
Recent Developments
QIAGEN N.V.
Recent Developments
Thermo Fisher Scientific Inc.
Recent Developments
Myriad Genetics Inc.
Recent Developments
Chapter 9 Company Profiles
ABCODIA LTD.
ADMERA HEALTH
ADX NEUROSCIENCES NV
AMPRION INC.
BIO-RAD LABORATORIES INC.
COMPUGEN LTD.
EPIGENOMICS AG
MIRNAXBIOSENS, S.L
ONCIMMUNE LTD.
OPTOS PLC



List of Figures


Summary Figure : Global Market for Predisposition Biomarkers, by Application, 2018-2024
Figure 1 : Global New Cancer Cases, by Type, 2018
Figure 2 : Prevalence of Cancer, by Type, 2018
Figure 3 : BioMerieux Inc.: Revenue, by Region, 2018
Figure 4 : F. Hoffmann-La Roche Ltd.: Revenue, by Operating Segment, 2018
Figure 5 : Merck KGaA: Revenue, by Region, 2018
Figure 6 : QIAGEN N.V.: Revenue, by Region, 2018
Figure 7 : Thermo Fisher Scientific Inc.: Revenue, by Region, 2018
Figure 8 : Myriad Genetics Inc.: Revenue, by Operating Segment, 2018

 

List of Tables


Summary Table : Global Market for Predisposition Biomarkers, by Application, Through 2024
Table 1 : Global Market for Predisposition Biomarkers, by End User, Through 2024
Table 2 : Global Market for the Application of Predisposition Biomarkers in Hospitals, by Region, Through 2024
Table 3 : Global Market for the Application of Predisposition Biomarkers in Research Institutes by Region, Through 2024
Table 4 : Research Institutes Working on Cancer Studies Across the Globe
Table 5 : Global Market for Predisposition Biomarkers, by Application, Through 2024
Table 6 : Clinically Relevant Biomarkers for Lung Cancer
Table 7 : Global Market for Cancer Predisposition Biomarkers, by Region, Through 2024
Table 8 : Global Incidence and Prevalence of Common Neurological Diseases, 2017
Table 9 : Global Market for Neurological Predisposition Biomarkers, by Region, Through 2024
Table 10 : List of Biomarkers Associated with CVDs
Table 11 : Global Market for Predisposition Biomarkers for CVDs, by Region, Through 2024
Table 12 : Global Market for Diabetes Predisposition Biomarkers, by Region, Through 2024
Table 13 : Characteristics of Biomarkers for Prediabetes, Diabetes and Associated Complications
Table 14 : Global Market for Other Applications of Predisposition Biomarkers, by Region, Through 2024
Table 15 : Global Market for Predisposition Biomarkers, by Region, Through 2024
Table 16 : North American Market for Predisposition Biomarkers, by Country, Through 2024
Table 17 : North American Market for Predisposition Biomarkers, by End User, Through 2024
Table 18 : North American Market for Predisposition Biomarkers, by Application, Through 2024
Table 19 : Active Early Detection Research Network Grants in the U.S., 2019
Table 20 : Funding for Research on Biomarkers for Alzheimer’s in Canada
Table 21 : European Market for Predisposition Biomarkers, by Country, Through 2024
Table 22 : European Market for Predisposition Biomarkers, by End User, Through 2024
Table 23 : European Market for Predisposition Biomarkers, by Application, Through 2024
Table 24 : Cancer Incidences and Mortalities in Europe, 2018
Table 25 : Major Neurological Incidences in Europe in 2017
Table 26 : Asia-Pacific Market for Predisposition Biomarkers, by Country, Through 2024
Table 27 : Asia-Pacific Market for Predisposition Biomarkers, by Application, Through 2024
Table 28 : Asia-Pacific Market for Predisposition Biomarkers, by End User, Through 2024
Table 29 : Cancer Incidence and Mortalities in Asia-Pacific, 2018
Table 30 : Active Dementia Research Grants in Australia
Table 31 : Rest of the World Market for Predisposition Biomarkers, by Application, Through 2024
Table 32 : Rest of the World Market for Predisposition Biomarkers, by End User, Through 2024
Table 33 : Number of Patents, by Country, January 2015-May 2019
Table 34 : Number of Patents, by Company/Organization
Table 35 : Number of Patents Registered, by Year
Table 36 : BioMerieux Inc.: Financial Analysis, 2017 and 2018
Table 37 : F. Hoffmann-La Roche Ltd.: Financial Analysis, 2017 and 2018
Table 38 : Merck KGaA: Financial Analysis, 2017 and 2018
Table 39 : QIAGEN N.V.: Financial Analysis, 2017 and 2018
Table 40 : Thermo Fisher Scientific Inc.: Financial Analysis, 2017 and 2018
Table 41 : Myriad Genetics Inc.: Financial Analysis, 2017 and 2018